Linical Co., Ltd. (JP:2183)
:2183
Want to see JP:2183 full AI Analyst Report?
2183 Stock Chart & Stats
¥293.00
-¥1.00(-0.28%)
At close: 4:00 PM EST
¥293.00
-¥1.00(-0.28%)
Day’s Range― - ―
52-Week Range¥204.00 - ¥363.00
Previous CloseN/A
Volume36.50K
Average Volume (3M)14.99K
Market Cap
¥4.79B
Enterprise Value¥2.02B
Total Cash (Recent Filing)¥5.53B
Total Debt (Recent Filing)¥2.22B
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.44%
Share Statistics
EPS (TTM)-28.06
Shares Outstanding24,740,000
10 Day Avg. Volume18,600
30 Day Avg. Volume14,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.46
Price to Sales (P/S)0.67
P/FCF Ratio-3.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)29.7
Revenue Forecast (FY)¥13.00B
Bulls Say, Bears Say
Bulls Say
Stable CRO Business ModelLinical's fee-for-service CRO model is structurally durable: pharmaceutical and biotech sponsors regularly outsource clinical development to control costs and access expertise. This creates recurring project-based revenue and predictable demand over multi-month trial cycles, supporting steady cash generation when projects win.
Comprehensive Service OfferingHaving end-to-end trial capabilities (planning, operations, project execution) strengthens client relationships and cross-sell potential. Integrated services increase switching costs and improve revenue visibility across trial stages, which supports long-term client retention and margin stability versus niche providers.
Manageable LeverageA debt-to-equity near 0.57 indicates moderate leverage, giving Linical financial flexibility to absorb short-term shocks or finance working capital. Reasonable leverage supports access to credit and reduces immediate solvency risk, allowing time to execute operational turnaround or secure new contracts.
Bears Say
Revenue And Profitability DeclineA substantial revenue decline and the shift from modest profit to a large net loss signal weakening demand or execution failures. Persistent top-line pressure erodes operating leverage and margins, undermining the firm's ability to invest in business development and weakening long-term competitive positioning if trends persist.
Negative Cash Generation In 2026The move to negative operating and free cash flow reduces internal funding for operations and growth, raising near-term funding risk. Persistent cash burn can force external financing or cost cuts, constraining sales support and increasing the probability of dilution or harder financing terms over the coming months.
Shrinking Equity CushionMaterial declines in equity reduce the balance-sheet buffer against further losses and impair solvency metrics. A thinner equity base increases sensitivity to additional write-downs or cash deficits and limits the company's strategic flexibility to absorb setbacks without seeking dilutive or costly capital.
Linical Co., Ltd. News
2183 FAQ
What was Linical Co., Ltd.’s price range in the past 12 months?
Linical Co., Ltd. lowest stock price was ¥204.00 and its highest was ¥363.00 in the past 12 months.
What is Linical Co., Ltd.’s market cap?
Linical Co., Ltd.’s market cap is ¥4.79B.
When is Linical Co., Ltd.’s upcoming earnings report date?
Linical Co., Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 68 days.
How were Linical Co., Ltd.’s earnings last quarter?
Linical Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥78.73 earnings per share for the quarter, missing the consensus estimate of N/A by -¥78.73.
Is Linical Co., Ltd. overvalued?
According to Wall Street analysts Linical Co., Ltd.’s price is currently Overvalued.
Does Linical Co., Ltd. pay dividends?
Linical Co., Ltd. pays a Annually dividend of ¥7.937 which represents an annual dividend yield of 5.44%. See more information on Linical Co., Ltd. dividends here
What is Linical Co., Ltd.’s EPS estimate?
Linical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Linical Co., Ltd. have?
Linical Co., Ltd. has 24,740,000 shares outstanding.
What happened to Linical Co., Ltd.’s price movement after its last earnings report?
Linical Co., Ltd. reported an EPS of -¥78.73 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Linical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2183
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Linical Co., Ltd.
Linical Co., Ltd. specializes in offering a wide range of drug development services to pharmaceutical companies across the globe. The company primarily assists in the therapeutic areas of oncology and central nervous system disorders. Its offerings encompass strategic consulting, including comprehensive market analysis for emerging products, expert advice on regulatory affairs, and assistance with licensing agreements. Furthermore, Linical manages clinical research and development programs and provides outsourced medical affairs support. These comprehensive services cover both the operational and post-study phases. Operational aspects include project oversight, trial monitoring, quality assurance, vendor coordination, auditing, and administrative support for clinical studies. Post-study activities involve data management, biostatistical analysis, medical writing, pharmacovigilance (drug safety monitoring), and overall medical management. The company was established in 2005 and maintains its corporate headquarters in Osaka, Japan.
Technical Analysis
Trans Genic Inc.
―
MEDINET Co., Ltd.
―
TMS Co., Ltd.
―
Takara Bio Inc.
―
ReproCELL Inc.
―